MRI-Guided Radiation Therapy for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new type of radiation therapy called MRgART, which uses MRI guidance to target lung cancer, and compares it to the standard LINAC (linear accelerator) radiation treatment. The main aim is to determine if MRgART affects the heart differently from the usual treatment. Participants will undergo radiation therapy, MRI scans, blood tests, and complete quality of life surveys. The trial seeks individuals with certain types of lung or esophageal cancer near the heart, who are scheduled for a specific kind of radiation treatment. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that MR-guided adaptive radiation therapy (MRgART) is generally well-tolerated by patients with lung cancer. Studies have found that MRgART carries a low risk of serious side effects, allowing patients to handle the treatment well without major issues.
For LINAC radiation therapy, research indicates it is safe and effective for treating lung cancer. Studies report high success rates in controlling cancer in the treated area, and the treatment is generally safe for patients.
Both MRgART and LINAC have demonstrated promising safety in studies, suggesting they are well-tolerated by patients with similar conditions.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments because they offer a new way to target lung cancer using advanced imaging technology. MRgART (Magnetic Resonance-guided Adaptive Radiation Therapy) stands out by using real-time MRI to precisely target tumors, potentially reducing damage to surrounding healthy tissue. LINAC (Linear Accelerator) radiation therapy is already a standard in cancer treatment, but this trial explores how these two innovative approaches might improve precision and outcomes. By enhancing the accuracy of radiation delivery, both treatments could lead to fewer side effects and better preservation of lung function, which is a significant advancement over traditional radiation therapies that rely on CT scans for guidance.
What evidence suggests that this trial's treatments could be effective for lung cancer?
This trial will compare two types of radiation therapy for lung cancer: MRgART and LINAC. Research has shown that MRgART, a type of radiation therapy guided by MRI, effectively treats tumors, with 78% of patients responding well. On average, patients experienced no cancer progression for about 19.6 months and lived overall for about 28.4 months. This method is particularly beneficial for lung cancer as it adjusts for tumor movement during treatment. Participants in this trial may receive either MRgART or LINAC radiation therapy. LINAC has also proven effective for lung cancer, with local cancer control success rates ranging from 77% to 96% over three years. Both treatments offer promising ways to target cancer near the heart while potentially reducing damage to healthy heart tissue.15678
Who Is on the Research Team?
Carri Glide-Hurst, PhD, DABR, FAAPM
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
The HEARTS Trial is for individuals with thoracic cancers, such as lung cancer, thymoma, non-small cell lung cancer, and esophageal cancer. Participants will receive radiation therapy and must be able to undergo MRIs and bloodwork. They should also be willing to complete quality of life questionnaires.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either MRgART or LINAC radiation therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LINAC
- MRgART
Trial Overview
This trial compares two types of radiation treatments: standard linear accelerator (LINAC) treatment versus magnetic resonance-guided adaptive radiation therapy (MRgART). The study focuses on how these therapies affect the heart in patients with thoracic cancers.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants randomized to this arm will receive magnetic resonance-guided adaptive radiation therapy (MRgART)
Participants randomized to this arm will receive linear accelerator (LINAC) radiation therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Citations
Harnessing the Power of Radiotherapy for Lung Cancer
Compared with CT-based technologies, MR-Linac could offer superior soft tissue visualization, daily adaptive capability, real-time target ...
Dosimetric comparison of two linear accelerators for lung ...
A retrospective analysis was conducted on 40 lung cancer patients treated with the Edge accelerator. Treatment plans using both the Edge (Plan ...
Recent technical advancements and clinical applications of ...
We discuss the advantages, limitations, and future directions of MRgRT, with a focus on its role in enhancing treatment precision, reducing ...
A Comparative Study of Patients With Early-Stage Non ...
Overall, the local, regional, and distant control rates were 89.3%, 86.3%, and 87.4% at 2 years, and the OS was 67.5% and 32.8% at 2 and 5 years, respectively.
Long-term clinical results of early-stage lung cancer ...
Local control (LC) rates of lung SBRT treatment are outstanding, ranging between 77 and 96% at 3 years [10,11,12,13]. Overall survival (OS) ...
Safety and Efficacy of Stereotactic MR-Guided Adaptive ...
SMART with daily online adaptation achieved excellent local control and a favorable safety profile in ultracentral NSCLC, comparable to ...
Safety and Tolerability of Online Adaptive High-Field ...
The findings of this study suggest that online adaptive MR-guided radiotherapy is associated with a low risk of high-grade acute toxic effects.
Analysis of linear accelerator-based fractionated stereotactic ...
LINAC-FSRT is safe and effective in BM. BED10>55 Gy notably enhances OS post-LINAC-FSRT and may benefit LC. High BED10 FSRT with targeted therapy likely boosts ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.